Valion Bio price to sales ratio VBIO

Market value divided by revenue over the last twelve months, since 2023.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 5.7×; May 2026
3-year median: 25.2×
3-year range: 2.2× to 105×
Peer median: 0.0×

Valion Bio's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in May 2026, at 5.7×.

On the days it had one over the last 3 years, its median was 25.2×, from 2.2× in Mar 2025 to 105× in Aug 2023.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	5.7×	2.8×	7.9×
2025	5.9×	2.2×	83.8×
2024	43.7×	10.7×	47.4×
2023	36.6×	10.5×	105×

Against its peers

Companies in Drug Manufacturers - General nearest Valion Bio's size, closest first, today.

Company	Price to sales ratio
VBIOValion Bio	n/m
NXTSNexentis Technologies	n/m
LABTLakewood-Amedex Biotherapeutics	n/m
JAGXJaguar Health	0.0×
DCOYDecoy Therapeutics	n/m
SBFMSunshine Biopharma	0.0×
ARTLArtelo Biosciences	n/m
LNAILunai Bioworks	n/m
GNPXGenprex	n/m
GOVXGeoVax Labs	n/a
ONCOOnconetix	n/m
Peer median	0.0×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Valion Bio

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.